Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Provincial Landscape
Snapshot: 2026-10-21
Fujian Multiple Myeloma Active Trials & Centers
As of 2026-10-21, there are 23 active clinical trials for multiple myeloma hosted across 5 tertiary medical centers in Fujian (including Fujian Medical University Union Hospital, Zhongshan Hospital Xiamen University, The First Affiliated Hospital of Xiamen University, etc.).
Active Trials
23
Hospitals
5
Therapies
CAR-T Cell Therapy / Bispecific & Multispecific Antibodies / Monoclonal Antibodies / Oral Small-Molecule Agents
Participating Medical Centers (5)
Fujian Medical University Union HospitalZhongshan Hospital Xiamen UniversityThe First Affiliated Hospital of Xiamen UniversityThe First Affiliated Hospital of Fujian Medical UniversityFujian Cancer Hospital
Active Studies in Fujian (23)
Population synthesized by CMDNShowing 1 published English records of 23 registry trials.
Phase ICTR20232373
RecruitingA Phase I Clinical Trial of QLS32015 for Injection Evaluating Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy in Patients with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: GPRC5D × CD3-targeting bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Henan Cancer Hospital、Shandong Cancer Hospital affiliated to Shandong First Medical University、The First Affiliated Hospital of Nanchang University 等 11 家中心